Pulmonary Hypertension Goal PowerPoint Presentation

Slide 1 -

Pulmonary hypertensionGoal directed therapy Pulmonary Hypertension Programme University of Toronto FMD

Slide 2 -

Disclaimer (1999) Support from No one in particular

Slide 3 -

Disclaimer (2011) Support from Actelion Glaxo Pfizer United Therapeutics / Northern Therapeutics Gilead Lilly Bayer

Slide 4 -

ppt slide no 4 content not found

Slide 5 -

Goals Identify modifiable and non-modifiable prognostic factors in patients with pulmonary arterial hypertension Interpret changes in hemodynamics and other indicators of disease severity Recognize how therapy is targeted in patients with pulmonary hypertension

Slide 6 -

Dana Point Classification of PH Galiè N et al. Eur Heart J 2009; 30:2493-537 Galiè N et al. Eur Resp J 2009; 34:1219-63

Slide 7 -

ppt slide no 7 content not found

Slide 8 -

Caregiver burden Emergent themes were stresses on physical and mental well-being, Stress on social and personal lives, Threats to financial security and career paths. The interviewees reported a sense of isolation as related to dealing with a disease that is relatively unknown to the majority of friends and family.

Slide 9 -

“The unwillingness to admit to their loved-ones, or indeed to themselves, that the caregiver role was taxing, augmented the sense of isolation”

Slide 10 -

Vasoconstrictors Vasodilators An imbalance...

Slide 11 -

What is it?

Slide 12 -

ppt slide no 12 content not found

Slide 13 -

Echo measures of RV function TAPSE Tei Index = (a – b) / b Eccentricity index

Slide 14 -

Goals of treatment Improve quality of life Restore exercise capacity Improve survival

Slide 15 -

ppt slide no 15 content not found

Slide 16 -

ppt slide no 16 content not found

Slide 17 -

Treatment paradigm Add therapy for disease progression

Slide 18 -

2005; 25: 244–249 % of patients (n=169) 12 months 24 months Dead Off bosentan On dual agents On bosentan alone

Slide 19 -

Treatment paradigm Add therapy for disease progression Add therapy for failure to reach goals

Slide 20 -

ppt slide no 20 content not found

Slide 21 -

Respiratory Medicine (2010) 104, 1588e1607

Slide 22 -

Respiratory Medicine (2010) 104, 1588e1607

Slide 23 -

McLaughlin VV, et al. Circulation. 2002;106:1477-1482. 0 20 40 60 80 100 Survival (%) 0 12 24 36 48 60 72 84 No. at risk 162 33 95 70 48 30 20 10 Months FC=3 FC=4 p=0.0001 by log-rank test 84 72 60 48 36 24 12 0 100 80 60 40 20 0 FC=1 No. at risk: FC=2 FC=3 FC=4 Survival (%) Months Impact of Functional Class on Survival Functional Class at Baseline Functional Class at 17±15 mos 10 20 30 46 63 86 112 115

Slide 24 -

JACC Vol. 40, No. 4, 2002

Slide 25 -

Circulation. 2006;114:1482-1489

Slide 26 -

Circulation. 122(2):164-72, 2010 Jul 13. 2 Multivariate predictors of 1 year outcome in REVEAL Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD Figure 2. Cox proportional-hazards estimates for multivariable model of survival, limited to terms included in the final stepwise model. Parameters significantly associated with 1-year survival only in univariable analyses included the Borg dyspnea scale, right ventricular dysfunction, pulmonary vascular resistance (PVR) index, pulmonary capillary wedge pressure, cardiac index, mean pulmonary artery pressure, and total serum bilirubin. Candidate predictor variables that were not significant at the univariable level included Tei index, vasoreactivity, race, newly diagnosed PAH, and income. Missing Borg scale and missing PVR index were both associated with lower-than-average observed survival and were therefore considered candidate predictor variables. APAH indicates associated I PAH; ECHO, echocardiogram; FPAH, familial PAH; mRAP, mean right atrial pressure; PoPH, portopulmonary hypertension; and RHC, right heart catheterization. *Reference category: NYHA/WHO functional class (Fn) II or missing. +If N-terminal proBNP is available and BNP is not, listed cut points are replaced with 1500 pg/mL. ++Restricted to tests performed within 1 year of enrollment; otherwise, the indicator is set to 0.

Slide 27 -

REVEAL observed 1-year survival from time of enrollment according to predicted risk strata. Risk 1 yr survival Low > 95% Average 90-95% Mod high 85-90% High risk 70-85% Very high risk <70%

Slide 28 -

REVEAL observed 1-year survival from time of enrollment according to predicted risk strata. Risk 1 yr survival Protective factors Risk factors (Median) (Median) Low > 95% 1 1 Average 90-95% 0 2 Mod high 85-90% 0 3 High risk 70-85% 0 4 Very high risk <70% 0 6

Slide 29 -

15 possible risk factors 4 possible protective factors 0 - 22 Actual scores ranged from 1 – 15 With a mean of 7.4

Slide 30 -

Prevalent cases Incident cases

Slide 31 -

ppt slide no 31 content not found

Slide 32 -

Combination therapy 26 observational studies and 5 randomized trials were identified. PDE-5 inhibitor and prostanoids, 6/7 studies reported improvement in 6MWD, 6/8 studies reported improvement in functional class, 6/6 studies reported improvement in hemodynamics and 1/2 trials demonstrated improvement in quality of life and time-to-clinical worsening. ERA and prostanoids, 4/6 studies and 1 trial reported improvement in 6MWD, 3/3 studies and 1/4 trials reported improvement in functional class, 4/5 studies and 1/4 trials reported improvement in PAP. ERA and PDE-5 inhibitor, 4/7 studies reported an improvement in 6MWD, and 2/6 studies report improvement in functional class.

Slide 33 -

ppt slide no 33 content not found

Slide 34 -

ppt slide no 34 content not found

Slide 35 -

ppt slide no 35 content not found

Slide 36 -

Galiè N et al. Eur Heart J 2009; 30:2493-537 Galiè N et al. Eur Resp J 2009; 34:1219-63

Slide 37 -

Galiè N et al. Eur Heart J 2009; 30:2493-537 Galiè N et al. Eur Resp J 2009; 34:1219-63

Slide 38 -

PAH specific therapies are recommended in FC II patients Galiè N et al. Eur Heart J 2009; 30:2493-537 Galiè N et al. Eur Resp J 2009; 34:1219-63

Slide 39 -

ESC/ERS recommendations for FC III patients Galiè N et al. Eur Heart J 2009; 30:2493-537 Galiè N et al. Eur Resp J 2009; 34:1219-63

Slide 40 -

Prognostically important variablesand treatment goals

Slide 41 -

CHEST 2006; 130:214–217

Slide 42 -

ppt slide no 42 content not found

Slide 43 -

IIt’s best to avoid standing directly between a competitive jerk and his goals